VENTRUBA, Tomáš, Pavel VENTRUBA, Michal JEŠETA, Jana ŽÁKOVÁ, Eva LOUSOVÁ, Igor CRHA, Tereza SOURALOVÁ, Irena KOUTNÁ a Aleš HAMPL. The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic. Advances in Clinical and Experimental Medicine. WROCLAW: WROCLAW MEDICAL UNIV, 2023, roč. 32, č. 8, s. 901-907. ISSN 1899-5276. Dostupné z: https://dx.doi.org/10.17219/acem/158777.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic
Autoři VENTRUBA, Tomáš (203 Česká republika, garant, domácí), Pavel VENTRUBA (203 Česká republika, domácí), Michal JEŠETA (203 Česká republika, domácí), Jana ŽÁKOVÁ (203 Česká republika, domácí), Eva LOUSOVÁ (203 Česká republika, domácí), Igor CRHA (203 Česká republika, domácí), Tereza SOURALOVÁ (203 Česká republika, domácí), Irena KOUTNÁ (203 Česká republika, domácí) a Aleš HAMPL (203 Česká republika, domácí).
Vydání Advances in Clinical and Experimental Medicine, WROCLAW, WROCLAW MEDICAL UNIV, 2023, 1899-5276.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30214 Obstetrics and gynaecology
Stát vydavatele Polsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.100 v roce 2022
Kód RIV RIV/00216224:14110/23:00130892
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.17219/acem/158777
UT WoS 000931727500001
Klíčová slova anglicky stem cells; IVF; human; embryo; hESC
Štítky 14110240, 14110517, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 14. 2. 2024 13:01.
Anotace
Background. Human embryonic stem cells (hESCs) have the unique ability to differentiate into any cell type in the human body and to proliferate indefinitely. Cell therapies involving hESC have shown very promising results for the treatment of certain diseases and confirmed the safety of hESC-derived cells for humans. They are used in cell therapy, mainly in targeted therapy of diseases that are currently incurable. Objectives. The aim of this study was the derivation of clinical-grade hESCs usable in drug development, non-native medicine and cell therapy. Materials and methods. Embryos were thawed, cultivated to the blastocyst stage if necessary, and assisted hatching was subsequently performed. Embryoblasts were mechanically isolated using narrow needles. Each line was kept as a separate batch. The derived hESCs were cultured under hypoxic culture conditions (5% O2, 5% CO2, 37°C) in a NutriStem® hPSC XF Medium with a daily medium change. Results. From January 2018 to July 2020, 138 selected clients were asked for consent to donate embryos, of whom 52 did not respond, 19 terminated the storage of their embryos and 29 extended the storage. Only 38 clients (27.5%) agreed to donate embryos for the derivation of hESCs. At the same time, personal communication with clients took place and another 17 embryo donors were recruited. A total of 160 embryos from 55 donors aged 26–42 years were collected. The embryos were frozen at the blastocyst (33.1%) or morula (46.3%) stage. After the preparation of 64 embryos, embryoblasts were isolated and cultured. Finally, 7 hESC lines were obtained, 4 research-grade and 3 clinical-grade, the first in the Czech Republic. Conclusions. We established a current good manufacturing practice (cGMP)-defined xeno-free and feeder-free system for the derivation, culture and banking of clinical-grade hESC lines that are suitable for preclinical and clinical trials. The quality control testing with criteria concerning sterility, safety and characterization according to cGMP ensured the clinical-grade quality of hESC lines.
Návaznosti
MUNI/A/1301/2022, interní kód MUNázev: Zdroje pro tkáňové inženýrství 13
Investor: Masarykova univerzita, Zdroje pro tkáňové inženýrství 13
NV18-08-00412, projekt VaVNázev: Lidské embryonální kmenové buňky pro klinické aplikace: derivace a charakterizace
Investor: Ministerstvo zdravotnictví ČR, Lidské embryonální kmenové buňky pro klinické aplikace: derivace a charakterizace
VytisknoutZobrazeno: 18. 7. 2024 11:27